• Citer

The EORTC module for quality of life in patients with thyroid cancer: Phase III

par Singer, Susanne;Kiyota, Naomi;Brannan, Christine;Salem, Dina;Gamper, Eva Maria;Arraras, Juan Ignacio;Ioannidis, Georgios;Andry, Guy ;Inhestern, Johanna;Grégoire, Vincent;Licitra, Lisa;Jordan, Susan;Locati, Laura Deborah;Pinto, Monica;Tomaszewska, Iwona I.M.;Araújo, Cláudia;Hammerlid, Eva;Vidhubala, E.;Husson, Olga
Référence Endocrine-related cancer, 24, 4, page (197-207)
Publication Publié, 2017-04

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The purpose of the study was to pilot-test a questionnaire measuring healthrelated quality of life (QoL) in thyroid cancer patients to be used with the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C30. A provisional questionnaire with 47 items was administered to patients treated for thyroid cancer within the last 2 years. Patients were interviewed about time and help needed to complete the questionnaire, and whether they found the items understandable, confusing or annoying. Items were kept in the questionnaire if they fulfilled pre-defined criteria: relevant to the patients, easy to understand, not confusing, few missing values, neither floor nor ceiling effects, and high variance. A total of 182 thyroid cancer patients in 15 countries participated (n = 115 with papillary, n = 31 with follicular, n = 22 with medullary, n = 6 with anaplastic, and n = 8 with other types of thyroid cancer). Sixty-six percent of the patients needed 15 min or less to complete the questionnaire. Of the 47 items, 31 fulfilled the predefined criteria and were kept unchanged, 14 were removed, and 2 were changed. Shoulder dysfunction was mentioned by 5 patients as missing and an item covering this issue was added. To conclude, the EORTC quality of life module for thyroid cancer (EORTC QLQ-THY34) is ready for the final validation phase IV.